Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Authors

Michael Konstan

Published

December 21, 2016

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Respiratory Medicine

Topics

Medicine

Pathology

Internal Medicine

Pulmonary And Respiratory Medicine

Cystic Fibrosis

DOI

10.1016/s2213-2600(16)30427-1

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Authors

Michael Konstan

Published

December 21, 2016

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Respiratory Medicine

Topics

Medicine

Pathology

Internal Medicine

Pulmonary And Respiratory Medicine

Cystic Fibrosis

DOI

10.1016/s2213-2600(16)30427-1

Paper

Paper

Paper

Paper

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Abstract

Supporters

Journal

Topics

DOI

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Abstract

Supporters

Journal

Topics

DOI